(+)-JQ1 is a novel, potent and highly specific BET (Bromodomain and extra terminal domain) bromodomain inhibitor with antineoplastic activity.

BMS-986158 (BMS986158; BMS 986158) is a novel, potent and selective BET (bromodomain and extra-terminal) protein inhibitor with potential antineoplastic activity.

BI-9564 is a novel, cell-permeable, noncytotoxic, potent, and selective inhibitor of BRD9 (bromodomain-containing protein) and BRD7 BD (bromodomains) with Kd values of 14.1 and 239 nM, and IC50 values of 75 nM and 3.4 µM for BRD9/7 respectively.

CPI-637 is a novel, potent, selective and cell-bioactive benzodiazepinone analog that acts as a CBP/EP300 bromodomain inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively.

(+)-JQ1 carboxylic acid is the free carboxylic acid (COOH) form of (+)-JQ1 (tert-Butyl ester form-COOtBu).

UNC669 (UNC-669) is a novel, potent and selective inhibitor of malignant brain tumor (MBT) with anticancer activity.

NI-57 is a potent inhibitor of the bromodomains of BRPF proteins that binds to BRPF1B, BRPF2, and BRPF3 with Kd values of 31, 108, and 408 nM, respectively

GSK9311 is an analog of GSK-6853, which is a benzimidazolone analog and a novel potent and highly selective inhibitor of the BRPF1 (Bromodomain and PHD Finger-containing) bromodomain with micromolar activity in a cellular target engagement assay, it shows excellent BRPF1 potency (pKd 9.5) and greater than 1600-fold selectivity over all other bromodomains tested.

BET-BAY 002 S enantiomer is the S-enantiomer of BET-BAY 002 which is a novel and potent BET (Bromodomain and extra-terminal ) inhibitor.

GSK4028 is the enantiomeric isomer and a negative control of GSK4027, which is a PCAF/GCN5 bromodomain chemical probe, the pIC50 of GSK4028 is 4.9 in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.